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Elizabeth C Chalom6, Lawrence K Jung7, Karen B Onel8, Lisa Petiniot9, Donald P Goldsmith10, Kabita Nanda11,12,
Michael Shishov13, Staci Abramsky1, James P Young14 and Edward H Giannini2 for the Pediatric Rheumatology
Collaborative Study Group
Abstract
Background: This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis
(JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs
(nsNSAIDs).
Methods: Children aged ≥2 to <18 years with rheumatoid-factor–positive or –negative polyarthritis, persistent or
extended oligoarthritis, or systemic arthritis were enrolled into this prospective, observational, multicenter standard-
of-care registry. Eligible patients were newly or recently prescribed (≤6 months) an nsNSAID or celecoxib. Enrolled
patients were followed to the end of the study, whether they remained on the original NSAID, switched, or discontinued
therapy altogether. All adverse events (AEs) regardless of severity were captured in the database.
Results: A total of 274 patients (nsNSAID, n = 219; celecoxib, n = 55) were observed for 410 patient-years of observation.
Naproxen, meloxicam, and nabumetone were the most frequently used nsNSAIDs. At baseline, the celecoxib group was
older, had a numerically longer median time since diagnosis, and a numerically higher proportion of patients with a
history of gastrointestinal-related NSAID intolerance. AEs reported were those frequently observed with NSAID
treatment and were similar across groups (nsNSAIDs: 52.0%; celecoxib: 52.9%). Twelve unique patients experienced
a total of 18 serious AEs; the most frequent were infections, and none was attributed to NSAID use.
Conclusions: The safety profile of celecoxib and nsNSAIDs appears similar overall. The results from this registry, ongoing
pharmacovigilance, and the phase 3 trial that led to the approval of celecoxib for children with JIA provide evidence that
the benefit-risk for celecoxib treatment in JIA remains positive.
Trial registration: ClinicalTrials.gov identifier NCT00688545.
Keywords: Celecoxib, Juvenile idiopathic arthritis, NSAIDs, Safety
Background
Even in this age of targeted biologic therapies such as
tumor necrosis factor-α inhibitors, nonsteroidal anti-
inflammatory drugs (NSAIDs) are integral to the treat-
ment of juvenile idiopathic arthritis (JIA). NSAIDs may be
the only therapy required for symptom control in some
patients with JIA, and when used as an adjunct to a
disease-modifying antirheumatic drug (DMARD), clinical
responses to NSAID therapy can be quite robust [1-6].
NSAIDs that inhibit both cyclooxygenase (COX)-1
and -2 enzymes (ie, nonselective or nsNSAIDs) are used in
a large majority of patients with JIA, although few NSAIDs
have been approved for this indication by regulatory agen-
cies. As of 2005, the only nsNSAIDs approved for the treat-
ment of JIA by the US Food and Drug Administration
(FDA) were naproxen, ibuprofen, tolmetin, oxaprozin, and
meloxicam. Of the COX-2–selective NSAIDs, rofecoxib
(Merck) was approved for JIA in 2004; in December 2006
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the FDA approved celecoxib (Pfizer) to treat the signs
and symptoms of juvenile rheumatoid arthritis (JRA) in
children aged 2–17 years. This approval was based on a
double-blind randomized controlled study that compared
celecoxib with naproxen in 242 patients over a 12-week
period, with a 12-week open-label extension of 202
patients, contributing a total of 100 patient-years (PY)
of exposure for celecoxib. The study demonstrated that
the efficacy of celecoxib is noninferior to naproxen,
with similar safety and tolerability profiles [3].
In late 2004, rofecoxib was voluntarily withdrawn globally
due to cardiovascular (CV) safety concerns in adults. In
2005, another selective NSAID, valdecoxib (Pfizer), was also
voluntarily withdrawn due to an unfavorable risk profile in
adults, which in part related to the occurrence of severe
cutaneous adverse reactions. Studies in adults have sug-
gested that users of any NSAID may be at increased risk
of CV outcomes, independent of the degree of selectivity
of COX-2 inhibition [7]. The FDA reviewed the available
data for all NSAIDs in 2005 and determined that celecox-
ib’s benefits outweighed its risks for appropriate patients.
While children have a very low risk of CV thrombo-
embolic and serious gastrointestinal (GI) events, many
patients with JIA will enter adulthood with arthritis and
may require NSAID therapy for prolonged periods. Know-
ledge regarding adverse effects and long-term sequelae of
treating children with NSAIDs is limited. The develop-
ment program for celecoxib was similar to those for other
NSAIDs approved for JIA; none of these programs were
sufficiently large (median size, 59 patients) nor exposed
patients for a long duration (median duration, 12 weeks)
to exclude rare or latent effects of treatment.
To address the need for longer-term data from routine
clinical practice regarding the safety of these medications
in JIA patients and to fulfill a postapproval commitment to
the FDA, we conducted the Safety in Idiopathic Arthritis:
NSAIDs and Celebrex Evaluation Registry (SINCERE™;
ClinicalTrials.gov identifier #NCT00688545).
SINCERE was a phase 4 observational multicenter
registry designed to collect longer-term safety data and
measures of development (defined as growth velocity and
pubertal maturation) from JIA patients in the United
States who were prescribed celecoxib or nsNSAIDs. In
consultation with the FDA, the study ended early due to
difficulties in celecoxib patient recruitment as a result of
an evolving JIA treatment paradigm that shortened the
recommended duration of NSAID use, and the very low
incidence rate of observed serious adverse events (SAEs).
Methods
This was a multicenter, single-country (United States),
prospective, observational registry of children and ado-
lescents aged ≥2 to <18 years treated with celecoxib or
nsNSAIDs by the treating rheumatologist for the signs
and symptoms of select categories of JIA conducted from
2009–2012. Categories included persistent or extended
oligoarthritis, rheumatoid-factor–positive or –negative
polyarthritis, or systemic arthritis (without presence of
extra-articular features for ≥6 months prior to enrollment)
[8]. Enthesitis-related arthritis and psoriatic arthritis
subtypes of JIA were excluded from the study popula-
tion since celecoxib was approved under the older JRA
indication. Given the expected recruitment difficulties
in this rare disease and the treatment paradigm in which a
child’s general pediatrician often initially prescribes an
NSAID while waiting for further evaluation and, if neces-
sary, referral to a pediatric rheumatologist, we could not
restrict the study population to a true inception or new
user design. Patients were eligible for participation if they
received a prescription for celecoxib or an nsNSAID
not more than 6 months prior (a quasi-inception cohort),
although previous cumulative exposure to NSAIDs could
exceed 6 months. Enrollment was subsequent to the rheu-
matologist’s decision to initiate or change an NSAID.
Registry assessments were performed at baseline, at
approximately months 4, 8, and 12, and twice yearly there-
after. The minimum requested follow-up in the study was
2 years, with a target total sample size of 400 patients, 200
each in the celecoxib and nsNSAID arms.
Data collected included safety information, defined as
all adverse events (AEs) and developmental outcomes
(height, weight, and age of menarche if appropriate). The
Gastrointestinal Scale for Kids (GISSK) instrument [9]
served to assess GI tolerability at baseline and to screen
for potential GI AEs during follow-up.
The following additional assessments were conducted:
the Childhood Health Assessment Questionnaire [10] at
baseline; the rheumatologic joint assessment at the initial
and final visits, the physician’s global assessment of disease
activity, and the parent assessment of overall well-being
(both measured on an 11-point ordinal scale ranging from
0–10) at each visit.
Drug information and supplies
The choice of study NSAID (celecoxib or nsNSAID),
dosage, frequency, and any adjustments thereof were at
the treating rheumatologist’s discretion. NSAID switches
and discontinuations were recorded, and patients remained
under follow-up, even if no longer using any NSAID.
Concomitant medications
Concomitant DMARDs or biologics, or changes in these
medications, were permissible as per the clinical judg-
ment of the treating physician. Concurrent treatment
with >1 NSAID was not allowed, though occasional use
of a second nsNSAID or acetaminophen for pain or
antipyresis was permitted.
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JIA diagnosis change
If a patient’s new diagnosis was another JIA category
(eg, psoriatic arthritis or enthesitis-related arthritis), they
remained in the study; the patient was withdrawn if the
new diagnosis was another rheumatic or nonrheumatic
disease (eg, lupus, fibromyalgia, or cancer).
AE reporting
An AE was defined as any untoward medical occurrence
in a study patient as assessed by the treating physician.
An SAE was defined as any AE that resulted in death, was
life-threatening, required hospitalization or prolongation
of existing hospitalization, resulted in persistent or signi-
ficant disability, or resulted in congenital anomaly. Preg-
nancy in a patient or patient’s partner was to be reported
as an SAE, even if no AE occurred in the mother or child.
The reporting period for all AEs extended from the time
the patient provided informed consent through and
including 28 calendar days after the last study visit.
Growth velocity and pubertal maturation
Growth (height and weight) was assessed via chart abstrac-
tion for the year prior to enrollment and at each study en-
counter throughout the registry. Standard age-appropriate
growth charts from the US Centers for Disease Control
and Prevention [11] were utilized to monitor for important
deviations from the norm. Age of menarche was recorded
at enrollment or at later study encounter.
Outcomes of interest
To address concerns about GI and CV safety with NSAIDs,
several events of special interest were defined a priori:
GI events consisted of ulcers or complications thereof;
CV/cardiorenal events comprised thromboembolic events
or new-onset/worsening hypertension; and new-onset or
worsening hypertension could be identified either as an
AE or via a change in antihypertensive drug use such as
initiation or an increase in dose. A post hoc composite GI
event category was developed to quantify GI tolerability
events, namely nausea/vomiting, abdominal pain, and all
other GI events.
Confounder and other assessments
The following factors were collected: demographics
(sex, race, age); targeted medical history, with particular
attention to GI risk factors; previous history of GI bleeds;
NSAID intolerability and other drug-related adverse reac-
tions; presence of hypertension, prior thromboembolic
disease, substantial changes in body weight, or other CV
risk factors; medications and dosage, and reason for ther-
apy switches or terminations; concomitant medications;
and early withdrawal from the registry, including reason.
Study ethics
The study protocol, informed consent, and assent docu-
mentation were reviewed and approved by the institu-
tional review board(s) at each investigational center. The
study was conducted in accordance with the Declaration
of Helsinki, International Conference of Harmonisation
Good Clinical Practice as appropriate, Good Pharmacoepi-
demiology Practices [12], and local regulatory requirements
and laws. The parent or legal guardian of each eligible
patient signed informed consent to participate in the
registry and a medical release form, and children signed
assent as required by the institutional review board(s).
Treatment classification
Patients who switched NSAID treatments during the
study were included in the treatment group that the
patient was in at the time the data were observed.
Changing from celecoxib to an nsNSAID (or vice versa)
was considered a treatment switch, while changing from
one nsNSAID to another was not.
Each participant’s total exposure time to each medication
was calculated for the full study, even if patients switched
medications. AEs were grouped in the main analysis
according to the NSAID (celecoxib or nsNSAID) utilized
at the time of the event, regardless of the initial NSAID
treatment at enrollment. The safety analysis set, which
was used for all analyses, consisted of all enrolled
patients who were prescribed at least 1 dose of any
NSAID, regardless of whether it was celecoxib or a
nsNSAID.
Statistical hypotheses and analyses
No a priori hypotheses were formulated for the analysis
as the primary intent of the registry was to collect
broad longer term safety information within this cohort
of NSAID users with JIA. No formal power analyses
were conducted because no comparative analyses were
performed.
Due to small sample size, incidence rate ratios were not
calculated, although incidence rates and 95% confidence
intervals (CIs) around the incidence rates were calculated
according to the method of Sahai and Khurshid [13] as
adapted for CIs around individual rates. Only descriptive
comparisons of baseline characteristics were performed
for the study.
Kaplan-Meier analysis was used to display cumulative
exposure time on initial NSAID treatment. SAS software
(version 9.1, SAS Institute Inc, Cary, NC) was used to
perform all analyses.
Results
Sixteen Pediatric Rheumatology Collaborative Study Group
member sites enrolled 274 patients from April 2009 until
January 2012.
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Baseline characteristics
A total of 219 (80%) patients received an nsNSAID as
initial treatment and 55 (20%) received celecoxib (Table 1).
The celecoxib group had a numerically higher mean
age than the nsNSAID group (10.0 vs. 8.2 years), with a
relatively lower proportion in the youngest age group
aged 2–5 years (14.5% vs. 35.2%) and a relatively greater
proportion in the oldest adolescent group aged 16–18
years (14.5% vs. 5.0%). Patients in the nsNSAID group
had a shorter median duration of disease by almost
8 months. Similar proportions of celecoxib (9.1%) and
nsNSAID (11.9%) users changed JIA diagnoses over the
course of the study.
The nsNSAID and celecoxib groups were similar at base-
line for the rheumatologic joint assessment, physician’s
global assessment of disease activity, and parent/subject
assessment of overall well-being (Table 1). Median weight
and height were numerically greater in the celecoxib
group than in the nsNSAID group, which is consistent
with the age difference. The celecoxib group also had
numerically worse results than the nsNSAID group at
baseline for all components of the Childhood Health
Assessment Questionnaire and GISSK. Differences be-
tween groups were greatest for the GISSK’s mean severity
score (celecoxib 21.9, nsNSAID 12.0) and percentages of
patients with specific problems, mainly lower stomach
pain (celecoxib 29.1%, other NSAID 15.5%) and nausea
(celecoxib 25.5%, nsNSAID 14.6%). Correspondingly, the
celecoxib group had a numerically higher proportion
of patients with a history of GI-related NSAID intoler-
ance consistent with other baseline assessments of GI
conditions.
Drug exposure and PY of observation
Mean duration of baseline treatment was similar for the
nsNSAID and celecoxib groups (12.5 and 11.2 months,
respectively). Exposure to baseline treatment was 228.1
PY for nsNSAIDs and 51.3 PY for celecoxib. Analysis of
cumulative time of study drug exposure during baseline
treatment after study enrollment did not indicate substan-
tial differences between groups in the distribution of time
on treatment (Figure 1). In addition, the proportion of
patients lost to follow-up over the course of the study
was small and equal in both groups (1.8%, representing
4 patients and 1 patient in the nsNSAID and celecoxib
groups, respectively).
Naproxen (47.8%), meloxicam (17.9%), and nabumetone
(6.6%) were the most frequently prescribed nsNSAIDs. At
the time of study termination, 79 patients (28.8% of total)
had discontinued NSAID treatment, 11 initially treated
with celecoxib and 68 initially treated with another
NSAID; furthermore, 67.6% of those on nsNSAIDs and
70.9% of those on celecoxib were receiving concomitant
medications for JIA (DMARDs, biologics, corticosteroids,
and analgesics).
NSAID treatments were switched at least once during
the study for 19 patients (6.9% of the total population).
There were 225 patients in the nsNSAID group (219 at
baseline and 6 switched from celecoxib) and 68 in the
celecoxib group (55 at baseline and 13 switched from
nsNSAIDs).
The mean observation time was 14.3 months in the
nsNSAID group and 12.0 months in the celecoxib group,
and 11.3 months for patients whose NSAID therapy was
discontinued ≥29 days after last dose of study medication;
the medians were generally similar. The study observed
patients for a total of 410.2 PY; individual study medica-
tion contributions can be found in Table 2. Mean total
follow-up time for all patients regardless of treatment
group and off-NSAID observation was 18.0 months.
Safety
As summarized in Table 3, all-causality AEs were reported
for similar percentages of patients during nsNSAID and
celecoxib treatment (52.0% vs. 52.9%), and during off-
NSAID observation (46.8%); the corresponding incidence
rates were 43.7, 52.9, and 49.6 per 100 PYs and the mean
duration of observation was similar among these groups.
Furthermore, the rates of temporary discontinuation were
low (<10.3%) but numerically more common in the cele-
coxib group.
Percentages of patients with any AE considered
treatment-related were similar with nsNSAID and cele-
coxib treatment (21.3% vs. 19.1%; Table 4). GI disorders
were the most frequently reported type of treatment-
related AE. Other types of treatment-related AEs were
reported for ≤2.9% patients during either study treatment;
7.6% of patients in the off-treatment group reported an AE
considered treatment-related.
SAEs were reported for 9 patients (4.0%) during
nsNSAID treatment, 2 events (2.9%) during celecoxib
treatment, and 3 events (3.8%) during off-NSAID observa-
tion (Table 5). There were 12 unique patients with SAEs be-
cause 2 patients had SAEs during more than 1 treatment/
observation period and were counted twice for this analysis.
Infections were the most frequently reported type of
SAE. In an analysis by baseline treatment group, the
SAE rate/100 PY was 3.0 (95% CI, 1.1–4.8) for patients
started on nsNSAID and 2.6 (95% CI, 0.0–6.3) for pa-
tients started on celecoxib. No SAE was thought to be
attributable to the study medications.
Only 2 patients had AEs of special interest (new-onset or
worsening hypertension for both) during study treatment
(nsNSAID in both cases; Table 2). Two additional AEs of
special interest (complications of GI ulcer and new-onset
or worsening hypertension) occurred at least 29 days after
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the study medication (initially treated with celecoxib and
nsNSAID, respectively) was stopped.
The incidence rates/100 PY for AEs of special interest
during nsNSAID treatment and off-NSAID observation
were small (0.7 [95% CI, 0–1.8] and 2.7 [95% CI, 0–6.4],
respectively). Percentages of patients with GI composite
AEs and incidence rates/100 PY of these AEs were gen-
erally similar for the nsNSAID and celecoxib groups.
Discussion
Celecoxib had safety outcomes similar to nsNSAIDs in a
total study population of 274 JIA patients followed for a
mean duration of approximately 18 months, correspond-
ing to a total of 410 PY of observation. These data add
considerably to the body of knowledge regarding NSAID
treatment of JIA. The pivotal celecoxib JIA trial [3], one of
Table 1 Patient demographics and other baseline
characteristics
nsNSAID
(n = 219)
Celecoxib
(n = 55)
Age, years, mean (SD) 8.2 (4.45) 10.0 (4.09)
Sex, n (%)
Male 54 (24.7) 8 (14.5)
Female 165 (75.3) 47 (85.5)
Race, n (%)
White 193 (88.1) 49 (89.1)
Black 16 (7.3) 5 (9.1)
Asian 6 (2.7) 0
Other 4 (1.8) 1 (1.8)
Ethnicity, n (%)
Hispanic or Latino 19 (8.7) 2 (3.6)
Non-Hispanic or Latino 200 (91.3) 53 (96.4)
Body mass index categories, n (%)
Underweight 10 (4.6) 6 (10.9)
Healthy weight 143 (65.3) 36 (65.5)
Overweight 38 (17.4) 8 (14.5)
Obese 20 (9.1) 4 (7.3)
Missing 8 (3.7) 1 (1.8)
Months since JIA diagnosis,
median (range)
4.25 (0–163.0) 12.10 (0.5–173.5)
JIA category, n (%)
Systemic 3 (1.4) 0
Persistent oligoarticular 119 (54.3) 27 (49.1)
Extended oligoarticular 12 (5.5) 2 (3.6)
Poly RF (–) 70 (32.0) 23 (41.8)
Poly RF (+) 14 (6.4) 3 (5.5)
Missing 1 (0.5) 0
Patients that have discontinued ≥1
NSAID in prior year,a n (%)
114 (52.1) 46 (83.6)
AE 16 (7.3) 25 (45.5)
Other reasons 64 (29.2) 15 (27.3)
Lack of efficacy 40 (18.3) 10 (18.2)
Both AE/lack of efficacy 3 (1.4) 4 (7.3)
Rheumatologic joint assessment,
mean (SD)
Number of joints with active arthritisb 2.9 (4.1) 3.4 (5.4)
Number of joints with swelling 2.7 (4.0) 3.1 (5.1)
Number of joints with pain on
motion/tenderness
1.7 (3.6) 2.5 (4.3)
Number of joints with loss of motion 1.7 (3.0) 1.9 (3.2)
Table 1 Patient demographics and other baseline
characteristics (Continued)
Childhood health assessment
questionnaire, median (range)
Functioning (in past week)c 0.35 (0–2.5) 0.44 (0–2.5)
Paind 0.45 (0–3.0) 0.66 (0–2.5)
Global evaluatione 14.00 (0–87.0) 16.50 (0–97.0)
Physician’s Global Assessment of
Disease Activity,f mean (SD)
2.9 (2.2) 2.6 (2.4)
Parent/subject assessment of
overall well being,g mean (SD)
2.8 (2.5) 3.2 (2.6)
aPatients discontinuing more than 1 NSAID for the same reason are only counted
once in the overall summary; however, if a patient discontinued an NSAID for
more than 1 reason, the patient contributes to the summary of each of
those reasons. bActive arthritis is defined as swelling of the joint or, if no swelling
is present, loss of motion accompanied by pain on motion or tenderness.
cFunctioning can range from 0–3, where higher scores indicate more impairment.
dPain can range from 0–3, where 0 = no pain and 3 = very severe pain.
eGlobal evaluation can range from 0–100, where 0 = very well and
100 = very poor.
fPhysician’s Global Assessment can range from 0–10, where 0 = not active and
10 = very active.
gParent/subject assessment of overall well-being can range from 0–10, where
0 = very well and 10 = very poorly.
Abbreviations AE: Adverse event, JIA Juvenile idiopathic arthritis, nsNSAID
Nonselective nonsteroidal anti-inflammatory drug, RF Rheumatoid factor.
Figure 1 Kaplan-Meier plot comparing cumulative time on
baseline study drug.
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the largest randomized trials of NSAIDs in JIA, followed
patients for 100 PY.
The analysis of AEs reported during study treatment
generally showed a similar incidence of AEs across groups,
and were those that are frequently observed with NSAID
treatment (eg, GI-related). Overall, the study results did
not indicate a difference in safety profile between cele-
coxib and other nsNSAIDs. However, the analysis is
limited by the study’s early termination and reduced
sample size as a result. The study would not be able to
adequately address the original research question regarding
the long-term safety of celecoxib in JIA patients due to
Table 2 AEs of special interest and composite gastrointestinal AEs by current treatment group (safety analysis set)
Variable/event type/AEa nsNSAID (n = 225b) Celecoxib (n = 68b) Off NSAIDc (n = 79)
Incidence, n (%)
Patients with at least 1 AE of special interest 2 (0.9) 0 2 (2.5)
GI 0 0 1 (1.3)
GI ulcer 0 0 0
Complications of GI ulcer 0 0 1 (1.3)
Cardiovascular/cardiorenal 2 (0.9) 0 1 (1.3)
Thromboembolic events 0 0 0
New-onset or worsening hypertension 2 (0.9) 0 1 (1.3)
Patients with at least 1 GI composite event 73 (32.4) 23 (33.8) 17 (21.5)
Abdominal pain 39 (17.3) 12 (17.6) 6 (7.6)
Nausea/vomiting 31 (13.8) 13 (19.1) 8 (10.1)
All other GI 44 (19.6) 11 (16.2) 11 (13.9)
Incidence rate (per 100 person-years), (95% CI)
Total person-years 267.6 68.0 74.6
Incidence rate of events of special interest 0.7 (0–1.8) 0 2.7 (0–6.4)
GI 0 0 1.3 (0–4.0)
Gl ulcer 0 0 0
Complications of GI ulcer 0 0 1.3 (0–4.0)
Cardiovascular/cardiorenal 0.7 (0–1.8) 0 1.3 (0–4.0)
Thromboembolic events 0 0 0
New-onset or worsening hypertension 0.7 (0–1.8) 0 1.3 (0–4.0)
Incidence rate of GI composite events 27.3 (21.0–33.5) 33.8 (20.0–47.6) 22.8 (12.0–33.6)
Abdominal pain 14.6 (10.0–19.1) 17.6 (7.7–27.6) 8.0 (1.6–14.5)
Nausea/vomiting 11.6 (7.5–15.7) 19.1 (8.7–29.5) 10.7 (3.3–18.2)
All other GI 16.4 (11.6–21.3) 16.2 (6.6–25.7) 14.7 (6.0–23.5)
aPatients are counted only once in each AE of interest category, and only once in each event type category.
bPatients will appear in both treatment groups if they switched treatments.
cOff NSAID is defined as 29 or more days after last dose of final study medication.
Abbreviations: AE Adverse event, CI Confidence interval GI Gastrointestinal, NSAID Nonsteroidal anti-inflammatory drug.
Table 3 Summary of AEs by current treatment group
AE category nsNSAID (n = 225a)
n (%)
Celecoxib (n = 68a)
n (%)
Off NSAIDb (n = 79)
n (%)
Patients with at least 1 AE 117 (52.0) 36 (52.9) 37 (46.8)
Patients with at least 1 AE causing temporary discontinuation 14 (6.2) 7 (10.3) 2 (2.5)
Patients with at least 1 serious AE 9 (4.0) 2 (2.9) 3 (3.8)
Patients with at least 1 AE of special interest 2 (0.9) 0 2 (2.5)
Patients with at least 1 GI composite eventc 73 (32.4) 23 (33.8) 17 (21.5)
aPatients who switch treatments contribute to both treatment groups.
bOff NSAID is defined as 29 or more days after last dose of final study medication.
cNausea/vomiting, abdominal pain, or all other GI.
Abbreviations: AE Adverse event, GI Gastrointestinal, nsNSAID Nonselective nonsteroidal anti-inflammatory drug.
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A) difficulties in celecoxib patient recruitment (despite
numerous attempts, only 20% of the 50% targeted was
ever achieved); B) the change in the JIA treatment para-
digm that emphasizes NSAID use for relatively short
periods of time [14,15], and C) the very low incidence
rate of observed SAEs. Furthermore, other accumulating
safety data from sources such as the pharmacovigilance
database and a simultaneously conducted active surveil-
lance program [16] did not suggest any new signals in the
JIA population.
The observational design demonstrated the expected
differences between prescribed groups in baseline charac-
teristics and baseline GI risk, indicative of confounding by
indication. For example, on study entry, compared with
nsNSAID users, the celecoxib users had evidence of more
severe JIA disease and longer disease duration, reflecting
the use of celecoxib as a second-line (or more) NSAID
therapy in JIA. As expected, a history of GI problems and
NSAID intolerance was more prevalent in celecoxib users,
suggesting that celecoxib was preferentially prescribed by
physicians to patients with a demonstrated history of
nsNSAID intolerance. Due to the very limited sample size
in the celecoxib group, methods such as propensity scores
or multivariable regression could not be adequately
addressed in analyses. However, based on the above,
the study results should provide a conservative estimate
Table 4 AEs considered treatment-related, by current treatment group
MedDRA system organ class/preferred terma nsNSAID (n = 225b)
n (%)
Celecoxib (n = 68b)
n (%)
Off NSAIDc (n = 79)
n (%)
Patients with at least 1 treatment-related AE 48 (21.3) 13 (19.1) 6 (7.6)
GI disorders (as shown below) 36 (16.0) 10 (14.7) 3 (3.8)
Abdominal pain 17 (7.6) 5 (7.4) 0
Nausea 8 (3.6) 3 (4.4) 1 (1.3)
Diarrhea 6 (2.7) 2 (2.9) 0
Dyspepsia 5 (2.2) 2 (2.9) 1 (1.3)
Gastroesophageal reflux disease 6 (2.7) 0 0
Constipation 4 (1.8) 0 1 (1.3)
Abdominal pain lower 3 (1.3) 0 0
Abdominal pain upper 1 (0.4) 2 (2.9) 0
Vomiting 0 1 (1.5) 1 (1.3)
Abdominal distension 1 (0.4) 0 0
Feces discolored 0 1 (1.5) 0
Gastritis 1 (0.4) 0 0
General disorders and administration site conditions 3 (1.3) 0 0
Immune system disorders (drug hypersensitivity) 1 (0.4) 0 0
Infections and infestations 1 (0.4) 0 1 (1.3)
Injury, poisoning, and procedural complications 4 (1.8) 0 0
Investigations 2 (0.9) 0 0
Blood pressure increased 1 (0.4) 0 0
Blood urea increased 1 (0.4) 0 0
Weight decreased 1 (0.4) 0 0
Metabolism and nutrition disorders 5 (2.2) 1 (1.5) 2 (2.5)
Musculoskeletal and connective tissue disorders 1 (0.4) 0 0
Nervous system disorders 6 (2.7) 0 0
Renal and urinary disorders 0 2 (2.9) 0
Reproductive system and breast disorders 0 1 (1.5) 0
Skin and subcutaneous tissue disorders 4 (1.8) 0 2 (2.5)
Vascular disorders 1 (0.4) 0 0
aPatients are counted only once in each preferred term category, and only once in each system organ class category.
bPatients appear in both treatment groups if they switched treatments.
cOff NSAID is defined as 29 or more days after last dose of final study medication.
Abbreviations: AE Adverse event, MedDRA Medical Dictionary for Regulatory Activities, GI Gastrointestinal, NSAID Nonsteroidal anti-inflammatory drug.
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of the safety of celecoxib compared with nsNSAIDs. It
should be noted that meloxicam, utilized by 18% of the
cohort, exhibits some COX-2–preferential selectivity in
some assays; in our analyses, we grouped it with the
nsNSAIDs, as the FDA considers it a nonselective NSAID.
SINCERE had numerous strengths. The broad inclusion
criteria reflect a more generalizable JIA population than
typically participate in randomized clinical trials for drug
registration. The demographics and clinical characteristics
of the study participants mirror the treated JIA population
in the literature [17], suggesting the study is representative
of JIA patients in general. Furthermore, the observational
design—with treatment assignment decided by the patient’s
treating rheumatologist—enabled assessment of actual
clinical practice and the “real-life” safety profile of
NSAIDs used for this disease. The study was designed a
priori to capture detailed information on GI and CV
risks and potential confounders to address potential
confounding by indication. Despite the early end, this
study had very little loss to follow-up for a longer-term
observational study (1.8% in each group), had very little
switching across NSAID groups (<7%), and recorded much
longer mean follow-up time (18 months) than published
randomized controlled trials of NSAIDs, which typically
had 3–6 months’ follow up.
There are several limitations of the registry. Early ter-
mination of the study and unexpectedly low celecoxib
use in the patient population did not allow for analyses
of growth velocity and pubertal maturation or formal
comparative safety analyses. Recruitment difficulties causing
Table 5 Serious adverse events by current NSAID treatment
Patient ID Current
medication
Onset-resolution
(daya)
Reported description Outcome Action taken
(study medication)
Causality
A nsNSAID 729–733 Cellulitis Resolved No action taken Other: spider bite
B nsNSAID 478–481 Benign fibrohistiocytic
lesions with giant cells
Resolved No action taken Other: idiopathic hip pain
C nsNSAID 303–307 Appendicitis Resolved No action taken Other: appendicitis
D nsNSAID 27–N/A Unintended pregnancy Unknown Permanently
discontinued
Other: pregnancy
E nsNSAID 33–39 Meningitis Resolved
with sequelae
Permanently
discontinued
Other illness:
infection—probably viral
F nsNSAID 160–167 Fever and neutropenia Resolved
with sequelae
Stopped temporarily Other illness: mycoplasma
infection
F nsNSAID 161–167 Agranulocytosis Resolved
with sequelae
No action taken Other illness: mycoplasma
infection
G nsNSAID 236–288 Infection musculoskeletal
septic arthritis
Resolved Stopped temporarily Other: unknown
H nsNSAID 205–N/A Onset of systemic JIA Still present Permanently
discontinued
Other: systemic JIA
I nsNSAID 93–149 Right lower quadrant
abdominal pain
Resolved Stopped temporarily Other: unknown possible
subclinical appendicitis
but pathology negative
I Celecoxib 138–149 Phlegmon Resolved Stopped temporarily Other: postsurgical
(appendectomy) complication
I Celecoxib 659–N/A Transformed migraine Still present Stopped temporarily Other illness: likely related
to past medical history
of migraines
J Celecoxib 82–246 Exacerbation of disease Resolved No action taken Disease under study
J Celecoxib 82–132 Fever Resolved No action taken Disease under study
K Off NSAID 69–N/A Primary sclerosing
cholangitis
Still present Permanently
discontinued
Other illness: primary
sclerosing cholangitis
G Off NSAID 452–N/A Septic arthritis Still present No action taken Other illness: septic arthritis
of unknown etiology
G Off NSAID 471–512 Acute tubular necrosis Resolved Permanently
discontinued
Other: vancomycin
L Off NSAID 424–429 Febrile neutropenia Resolved No action taken Other illness: infection
questionable Rocky
Mountain spotted fever
aRelative to the start of treatment.
Abbreviations: JIA Juvenile idiopathic arthritis, N/A Not available, nsNSAID Nonselective nonsteroidal anti-inflammatory drug.
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early termination or substantial extensions of enrollment
in pediatric studies are a well-known challenge [18-20].
Furthermore, the use of biologics approximately doubled
over the course of the study (data not shown) and is
consistent with the increasing prevalence of biologic use
with associated decline in NSAID use, as demonstrated in
a drug utilization study from a large US insurer [21]. The
duration of study treatment was relatively short and
thus longer-term or latent AEs could not be adequately
detected, but this short duration likely reflects actual
current clinical practice with NSAIDs [22] in the United
States, as suggested by recent guidelines from the American
College of Rheumatology on the treatment of JIA [14,15].
Extensive use of concomitant medications, especially
biologics and DMARDs, was a complicating factor for
attribution of observed AEs to study treatment. Selection
bias may have occurred; a new-user (NSAID-naïve) design
would have minimized this potential bias, but the
quasi-inception cohort design was chosen to maximize
generalizability and operational efficiency as the number
of celecoxib users was anticipated to be substantially less
than nsNSAID users. Lastly, as this study was conducted
exclusively in the United States, it is unknown whether
other regions would have the same findings.
Conclusions
The safety profile of celecoxib in JIA appears similar over-
all to that of nsNSAIDs, with few appreciable differences
observed in this study. The total study population of 274
patients observed for a total of 410 PY is the largest pro-
spectively followed JIA NSAID cohort to date, and adds
considerably to the safety experience of NSAID treatment
for JIA. Based on the findings of this study and the low
number of SAEs observed overall, no new safety concerns
were identified. These registry data, the ongoing pharma-
covigilance, and the results of the phase 3 trial that led to
the approval of celecoxib for children with JIA further
support a positive benefit-risk balance for celecoxib in JIA.
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